Connect with us

Hot News

The 1st Coronavirus Vaccine ‘mRNA-1273’ Ready for Human Experimental Test

Published

on

The 1st Coronavirus Vaccine has been discovered for experimental testing in United states of America.

The new vaccine is a collaboration between NIAID scientists and the biotechnology company Moderna Inc., based in Cambridge, Massachusetts.

Covid-19 which is the disease caused by Coronavirus has been a threat to human lives and National Economy systems. However, it seems that we are getting close to eliminating this deadly virus.

The vaccine was fast-tracked to human trials, but more time is needed before it’s ready for public use. A healthy volunteer in Seattle is the first person in the U.S.A. to receive a dose of an experimental coronavirus vaccine as part of a new clinical trial announced by the government health officials on March 16th.

Also Read: Coronavirus: Safety Health Measures Beyond the Surgical Mask and Hand Sanitizers

The National Institute of Allergy and Infectious Diseases (NIAID) allowed the new vaccine to be fast-tracked into clinical trials without thorough testing in animal models, which usually stands as a strict prerequisite to human testing. While making the jump to human trials could bring the vaccine to market faster, this is only step one.

In the next 6 weeks, researchers plan to enroll 45 participants in the trial, which will test the safety of the vaccine as well as its ability to induce an immune response in the volunteers. The trial will be taking place at Kaiser Permanente Washington Health Research Institute (KPWHRI) in Seattle.

However, NIAID Director Dr. Anthony Fauci told the House Oversight and Reform Committee that this new Vaccine must pass through 3 iterative phases of clinical trials before being deemed safe and effective for widespread use. Assuming the initial tests go well, it may take 12 to 18 months before any vaccine is ready for public use.  

“Finding a safe and effective vaccine to prevent infection with SARS-CoV-2 is an urgent public health priority,” Fauci said in a NIAID statement, published March 16. “This Phase 1 study, launched in record speed, is an important first step toward achieving that goal.”

PHASE 1 TRIAL:

According to the U.S. Food and Drug Administration (FDA), this trial launched today is known as a “Phase 1 clinical trial,” meaning its main purpose is to provide information about how the vaccine interacts with a healthy human body.

Phase 1 trials examine a small group of people, typically between 20 and 80 individuals, who received different doses of an experimental treatment. Over the course of several months, researchers monitor how each volunteer metabolizes the given treatment and what common side effects emerge in response to different doses.

The 45 volunteers in the new trial will receive varying doses of the new vaccine called ‘mRNA-1273’ and they will be monitored over a 14-month period.

Volunteers will receive two injections of the vaccine in the upper arm, with a 28-day gap between doses. The first participant will receive the lowest dose of the vaccine, at 25 micrograms (mcg) per injection, according to the NIAID statement.

Three others will receive the same initial dose, and four more will each receive a 100-mcg dose of the vaccine and be thoroughly evaluated before any volunteers are given their second dose.

According to ClinicalTrials.gov., if participants’ reactions to the low doses prove acceptable, a third group of participants will receive 250 mcg of the vaccine per injection. In addition to monitoring for side effects, the researchers will test whether the vaccine triggers an immune response by analyzing the volunteers’ blood for antibodies.

However, If the vaccine works as designed, the immune system should generate antibodies that grab hold of a characteristic protein found on the surface of the novel coronavirus SARS-CoV-2.

Kaiser Permanente, the health care company conducting the trial said instead of introducing a dead or weakened virus into the body to prompt this reaction, as conventional vaccines do, the vaccine instructs cells to build the viral protein themselves using a molecule called messenger RNA (mRNA). Once utilized by the body, the mRNA should break down and be eliminated, leaving only protective antibodies behind. 

PHASE 2 TRIAL:

According to the U.S. Centers for Disease Control and Prevention (CDC), the drug must then be tested in larger groups of people and over longer periods of time, in Phase 2 and Phase 3 trials.

Phase 2 trials typically examine several hundred people and monitor participants for periods of from several months to two years.

Worthy of note, Phase 2 trials serve as a secondary measure of safety and help researchers to refine the dosing of a particular medication. At this stage, researchers select participants with characteristics, such as age and physical health, that match those of the people who the vaccine is being developed for. (For example, although anyone can contract COVID-19, those of advanced age and those with chronic conditions are more likely to develop severe symptoms, so this could be a consideration in Phase 2 trials.)

PHASE 3 TRIAL:

According to the FDA, Phase 3 trials typically follows 300 to 3,000 volunteers over the course of one to four years; with a larger group of people, researchers can take note of unusual side effects of the drug, and by lengthening the study period, they can catch long-term side effects as they emerge.

Phase 3 trials must demonstrate that a given drug provides the medical benefits it’s intended to; if this coronavirus vaccine passes that test, the FDA could approve the drug for widespread use.

PHASE 4 TRIAL:

Following approval by the FDA, drugs undergo Phase 4 clinical trials, otherwise known as “post-marketing surveillance trials.” Once a drug enters public use, researchers monitor several thousand volunteers to spot side effects not seen in earlier trials and to track how well the vaccine works over extended periods of time, according to the National Cancer Institute.

Although this coronavirus vaccine may or may not reach Phase 4 trials in the coming years, limited studies have shown promising results. In the meantime, research groups around the world will continue to develop alternate vaccines to combat the spread of COVID-19.

Comments
Please follow and like us:
Advertisement
1 Comment

1 Comment

  1. Pingback: Coronavirus: Hydroxychloroquine Proving an Effective Treatment for Patients Around the World (Video) - Chinonyerem Emmanuella's Blog

Leave a Reply

Hot News

Arms Procurement Investigation: “Issues of arms procurement were done by specific individuals, call these individuals to explain to you ” – COAS Ibrahim Attahiru tells House of Reps members

Published

on


A dramatic scene was recorded today April 13 after the Chief of Army Staff Lieutenant General Ibrahim Attahiru appeared before House of Representatives ad-hoc committee on arms and ammunition as part of the investigation into arms purchase by the military.


Attahiru refused to speak on arms procurement after presenting a document to the committee.


According to the COAS, he just resumed office and the issues surrounding the procurement of arms should be answered by the “specific individuals” who initiated the purchase.


He said;


“The submission before you speaks to the report before you. It is an executive summary. It is very self-explanatory to the extent that it has been pluralised. When you demanded this report, you stated a specific period for which you wanted it.

“You may wish to recall that the Chief of Army Staff took over the mantle of leadership barely two months ago.

“The period for which you want this report having been summarised in the executive summary explained whatever details you require.

“Issues of arms procurement that you so demand to know were done by specific individuals, I will rather you call these individuals to explain to you very specific issues the general explanation is contained in this report.”


A member of the committee, Ejiro Ogene had also faulted the COAS explanation for not appearing before the committee earlier.


Ogene said;


“When we ask you to come, the people are the ones speaking, sovereignty lies in the people; if we see it like this, things will be different.

“I expect that the COAS tenders an apology, not an explanation; you are serving the people and they are as your employer.”


Firing back at him, Attahiru insisted that his explanation serves as an apology. He said;


“When you say I offered an explanation, it is as good as an apology. It only tells you the reasons why I wasn’t here and the reasons are pungent enough.”


Following the rising tension at the proceeding, Chairman of the Committee Olaide Akinremi ruled that the hearing goes into a closed-door meeting and the media were asked to leave the hearing.

Comments
Please follow and like us:
Continue Reading

Hot News

25-year-old Nigerian man arrested for Scamming woman of N16million in India

Published

on

 

A 25-year-old Nigerian has been arrested in India for allegedly scamming a 62-year-old woman from Indore, Madhya Pradesh, of Rs 31.64 lakh (N16,048,923.81)

“The accused, Wisdom Obinna, from Imo State, was part of a gang that befriended women on social media and then scam them with lottery and gift frauds,” said Indore Cyber Cell Superintendent of Police, Jitendra Singh, on Friday, April 9.

“Obinna was arrest25-year-old Nigerian man arrested in India for duping woman of N16m ed from Delhi, where he was staying even after his business visa expired. Efforts are on to nab other members of the gang,” he added.

ALSO READ;

During the interrogation, the accused said that he came to India on Business Visa in 2014 and 2017. After the visa expired, he became active in cheating and used to operate from Delhi.

The gang members befriend Indian girls and women on Facebook by creating accounts with different foreign fake IDs.

After Wisdom has made friends with the women, he lured his victims by claiming he sent them some expensive gifts.

Later, other members of the gang pose as custom officers and demand money in the name of Tax and Penalty to get the parcel, send a message through bank account WhatsApp and get the money transfer. They would also threaten the victim with legal action.

Police recovered eight passbooks of various banks, three ATM cards, two laptops, three pen drives, 9 mobile phones, eight SIM cards, two dongles, passports and Rs 11000 in cash from the accused.

 

25-year-old Nigerian man arrested in India for duping woman of N16m

Comments

Please follow and like us:
Continue Reading

Economy

CBN gets order to freeze 194 accounts in 17 banks

Published

on

CBN gets order to freeze 194 accounts in 17 banks

The Central Bank of Nigeria, CBN has secured three separate interim orders from a Federal High Court in Abuja to freeze bank accounts linked to 194 business entities and individuals in 17 banks.

This was contained in a post by the apex bank on its website yesterday pursuant to the court order. The freeze orders were sequel to three exparte applications filed by the apex bank seeking a mandatory order of the court to ask the 17 banks to freeze the account of the business organizations and individual pending the outcome of an ongoing investigation the apex bank had initiated.

In one of the suits against Nuru Abubakar and 24 others, the court granted the request by CBN to freeze the account of the defendants in the banks for 45 days. Justice A.R Muhammed who made the order in his ruling on March 30, 2021, said: “An interim order is hereby made empowering the applicant to direct the head office of the listed banks to freeze forthwith all transactions on the bank account of the defendants for a period of 45 days pending the outcome of investigation and inquiry currently being conducted by CBN.”

ALSO READ;

In another suit filed by CBN against Sethwealth Ventures and two others, the court granted an exparte application by the apex bank to freeze 50 accounts linked to the three defendants in 13 banks. A similar order was also made in the suit by CBN against Bluebeam Capital Ltd freezing 60 accounts of the company in 13 banks.

The 17 banks affected are Access Bank, First City Monument Bank, Fidelity Bank, Sterling Bank, Keystone Bank, Providus Bank, United Bank for Africa (UBA), Wema Bank and First Bank. Others are Guaranty Trust Bank, Ecobank Bank, Heritage Bank, Polaris Bank, Zenith Bank, Stanbic IBTC Bank, Standard Chartered Bank and Union Bank.

The companies affected include Bluebeam Capital Limited, Sethwealth Ventures, Seasons Bureau De Change, Lat-Ade Logistics, Sani Polo Global Investment Ltd, Saneo Global Resources Limited and Romvic Ventures Nigeria Limited.

 

Comments

Please follow and like us:
Continue Reading

Let’s keep you updated

Advertisement

Instagram

Recent Tweets

Trending

error

We know you enjoy our storylines. Please spread the word to your friends :)

%d bloggers like this:
Enable Notifications    OK No thanks